Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 4 of 26 · 1221 articles
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.
Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...
Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...
Researchers are exploring new oral delivery carriers that could deliver drugs directly to inflamed intestinal sites while also modulating immune responses and the gut microbiome. If translated, these approaches might...
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
Improving mesalazine delivery could increase drug reaching the colon and potentially improve treatment for ulcerative colitis. A formulation that both enhances dissolution/permeability and offers mechanistic synergy...
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...
The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from gastroendonews.com.
Patients with PsA and clinicians choosing long‑term biologic therapy may care about both durability of PsA control and safety signals for related inflammatory conditions like IBD and uveitis. This analysis reports...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Infliximab.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.
The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...
Knowing ustekinumab levels and anti-drug antibody status may help predict which people with Crohn’s disease are more likely to be in clinical remission and guide treatment adjustments.
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from BMJ case reports.
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from BMC Gastroenterology.
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
Starting biologic therapy within six months of Crohn’s diagnosis was associated with substantially higher rates of steroid-free remission at one year and less steroid dependence, suggesting earlier treatment could...
Based on the title and source metadata, this appears to be an opinion or commentary related to Inflammatory bowel disease and Medications. The original article is from Internal medicine journal.
People with UC and PSC have limited study data on microbiome-targeted therapies; this trial asks whether short-course oral vancomycin is feasible and safe in this specific group and will look for early signals in...
Adherence to biologic therapy can affect how well treatment controls IBD; understanding whether self-administered subcutaneous vedolizumab has different adherence than IV infusion could influence treatment choices and...
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
A rapidly growing abdominal mass or unexplained systemic decline in someone with Crohn's disease may represent a rare malignancy (plasmablastic neoplasm) rather than infection or a disease flare; prompt biopsy is...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and...
People with IBD or their clinicians may see signals suggesting certain drugs are more often reported with ulcerative colitis; this study combines adverse‑event reports with gene‑expression comparisons to help prioritize...
Researchers exploring new anti-inflammatory or metabolism-targeting approaches for UC might view KA as a candidate molecule that modulates arginine–polyamine metabolism, which could point to new drug-discovery...
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
Postoperative recurrence after ileocolonic resection is common and identifying who is at higher risk helps guide postoperative monitoring and decisions about early prophylactic therapy.
Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...
Pulmonary nodules appear more frequently in people with Crohn’s disease and have distinct patterns over time. Knowing which factors predict nodule burden can help clinicians prioritize monitoring and interpret chest...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Crohn's & colitis 360.
People with UC often try complementary therapies; this review shows that benefits and risks vary by specific CHM product and that current evidence is mixed and product-dependent.
